Patents by Inventor Murugan Avaniyapuram Kannan

Murugan Avaniyapuram Kannan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
    Patent number: 9150929
    Abstract: The present invention relates to diagnostic, therapeutic and prognostic methods for thyroid cancers. In one embodiment, the present invention provides a method for treating a an anaplastic thyroid cancer (ATC) patient comprising the step of administering to the patient an effective amount of an anaplastic lymphoma kinase (ALK) inhibitor. In another embodiment, a method for diagnosing ATC in patient comprises the step of performing an assay on a biological sample from the patient to identify the presence or absence of a C3592T and/or a G3602A mutation in exon 23 of the ALK gene according to SEQ ID NO:6, wherein the presence of either of both of the mutations correlates with a diagnosis of ATC in the patient.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: October 6, 2015
    Assignee: The Johns Hopkins University
    Inventors: Michael Mingzhao Xing, Murugan Avaniyapuram Kannan
  • ANAPLASTIC THYROID CANCERS HARBOR NOVEL ONCOGENIC MUTATIONS OF THE ALK GENE
    Publication number: 20140128432
    Abstract: The present invention relates to diagnostic, therapeutic and prognostic methods for thyroid cancers. In one embodiment, the present invention provides a method for treating a an anaplastic thyroid cancer (ATC) patient comprising the step of administering to the patient an effective amount of an anaplastic lymphoma kinase (ALK) inhibitor. In another embodiment, a method for diagnosing ATC in patient comprises the step of performing an assay on a biological sample from the patient to identify the presence or absence of a C3592T and/or a G3602A mutation in exon 23 of the ALK gene according to SEQ ID NO:6, wherein the presence of either of both of the mutations correlates with a diagnosis of ATC in the patient.
    Type: Application
    Filed: May 7, 2012
    Publication date: May 8, 2014
    Inventors: Michael Mingzhao Xing, Murugan Avaniyapuram Kannan